首頁 > 市場調查報告書 > 製藥

基因治療學和RNAi

市場調查報告書

商品編碼

1327712

RNAi藥物遞送：技術和全球市場

RNAi Drug Delivery: Technologies and Global Markets

出版日期: 2023年08月08日 | 出版商:

BCC Research | 英文 141 Pages | 訂單完成後即時交付

價格

簡介目錄圖表

全球核酸藥物輸送市場規模預計將從2023年的11億美元成長到2028年的27億美元，預測期內年複合成長率為20.5%。

按類型分類，封裝行業預計將從2023年的 6.294 億美元成長到2028年的 17 億美元，年複合成長率為 22.1%。此外，結合行業預計將從2023年的 4.326 億美元成長到2028年的 9.846 億美元，年複合成長率為 17.9%。

本報告調查全球RNAi藥物遞送市場，提供了市場概況、市場影響因素和市場機會分析、市場規模轉變和預測、各個細分市場和地區的詳細分析、ESG的發展、新興技術，並總結了新的發展、競爭形勢、主要企業簡介等等。

ALNYLAM PHARMACEUTICALS INC.
ARCTURUS THERAPEUTICS INC.
ARBUTUS BIOPHARMA CORP.
ARROWHEAD PHARMACEUTICALS INC.
BENITEC BIOPHARMA
CELLECTA INC.
ELEVEN THERAPEUTICS
GENEVANT SCIENCES CORP.
IONIS PHARMACEUTICALS INC.
MIRIMUS, INC.
NOVO NORDISK
NANODE THERAPEUTICS INC.
OLIX PHARMACEUTICALS
PHIO PHARMACEUTICALS CORP.
SILENCE THERAPEUTICS PLC
SIRNAOMICS INC.
SOMAGENICS, INC.

簡介目錄圖表

Product Code: BIO076C

Highlights:

The global nucleic acid drug delivery market should reach $2.7 billion by 2028 from $1.1 billion in 2023 at a compound annual growth rate (CAGR) of 20.5% for the forecast period of 2023 to 2028.

Encapsulated segment of the global nucleic acid drug delivery market is expected to grow from $629.4 million in 2023 to $1.7 billion in 2028 at a CAGR of 22.1% for the forecast period of 2023 to 2028.

Conjugated segment of the global nucleic acid drug delivery market is expected to grow from $432.6 million in 2023 to $984.6 million in 2028 at a CAGR of 17.9% for the forecast period of 2023 to 2028.

Report Scope:

This research report categorizes the market for nucleic acid drugs by type. The major product segments are conjugated and encapsulated. The non-viral vectors used for encapsulation are divided into polymers, lipids and others (e.g., inorganic material, hybrid systems). The market is also segmented based on the molecule types, delivery modes and therapeutic areas. It is divided by application types into therapeutic applications and research-based applications. The markets in North America, Europe, the Asia-Pacific region and Rest of the World (RoW) are covered.

Report Includes:

24 data tables and 45 additional tables
An up-to-date overview and industry analysis of the global markets for RNA interference (RNAi) drug delivery technologies
Analyses of the global market trends, with historic market revenue (sales figures) from 2020 to 2022, estimates for 2023, and projections of compound annual growth rates (CAGRs) through 2028
Estimation of the actual market size and revenue forecast for the RNAi drug delivery technologies market, and corresponding market share analysis based on type of RNAi, therapeutic area, and region
Discussion of major growth drivers, industry-specific challenges, regulatory aspects, and technology advancement that will shape the market for RNAi drug delivery technologies as a basis for projecting demand in the next few years (2023-2028)
Review of key patent grants and patent applications on RNAi drug delivery markets, and emerging technologies and new developments within the marketplace
Latest information on the mergers and acquisition deals, partnerships, agreements, collaborations, and other strategic alliances within the marketplace
Insight into the recent industry structure, competitive aspects of each product segments, increasing investment on R&D activities, market growth strategies, and company revenue share analysis
A look at commercial opportunities in the RNAi research tools and reagents, recent progress and future opportunities for RNAi therapeutics in various disease classifications, clinical trial applications, and potential markets for future developments
Identification of the major stakeholders and analysis of the competitive landscape based on recent developments, segmental revenues, and operational integration
Descriptive company profiles of the leading global players of the industry, including Alnylam Pharmaceuticals, Benitec Biopharma, Ionis Phamaceutical, Novo Nordisk and Sirnaomics Inc.

Chapter 1 Introduction

Study Goals and Objectives
Reasons for Doing the Study
Scope of Report
What's New in This Update?
Research Methodology
Geographic Breakdown

Chapter 2 Summary and Highlights

Market Outlook

Chapter 3 Market Overview

Introduction
History of Nucleic Acid Drugs
Antisense Oligonucleotides
RNA
Drug Delivery System
Nucleic Acid Drugs
Inhibition Type
Antisense Oligonucleotide
Regulations
Pre-Clinical INDA
COVID-19 Impact Analysis on the RNAi Drug Delivery Markets
Positive Impact of COVID-19
Negative Effect of COVID-19

Chapter 4 Market Dynamics

Market Drivers
Approved RNAi Drugs
Venture Funding Increased in RNAi Drugs
RNAi Drugs Designated as Orphan Drugs
New Nanoparticle Technologies for Drug Delivery Systems
Market Restraints
High Drug Costs
Lack of Awareness Regarding Rare Diseases
Clustered Regularly Interspaced Short Palindromic Repeats Technology Application Growing
Market Opportunities
Application in Cancer Treatment
Infectious Disease and RNAi Drugs

Chapter 5 Nucleic Acid Drug Delivery Technology Market by Type

Encapsulation
Viral Vector-Based
Non-Viral Vector-Based Delivery System
Conjugates

Chapter 6 Market Breakdown by Application

Drug Development and Discovery
Process of RNA-Based Drug Discovery
Design of RNAi Drugs
Sequence Optimization
Chemical Modification
Targeted Delivery
Therapeutic Application

Chapter 7 Market Breakdown by Route of Administration

Chapter 8 Market Breakdown by Molecules

Small Interfering Ribonucleic Acid
Antisense Oligonucleotide
Fomivirsen (Vitravene)
Mipomersen
Nusinersen (Spinraza)
Inotersen (Tegsedi)
Eteplirsen (Exondys 51)
Golodirsen (Vyondys 53)
Milasen: A Unique Personalized Medicine
Messenger RNA
Others
Aptamers
Micro RNA

Chapter 9 Market Breakdown by Therapeutic Area

Oncology
Rare and Genetic Diseases
Central Nervous System
Respiratory
Other Disease

Chapter 10 Market Breakdown by Region

North America
Europe
Asia-Pacific
Japan
South Korea
China
India
Australia
Rest of the World

Chapter 11 Environmental, Social and Governance in the Biotechnology Sector

Key Environmental, Social and Governance Issues in the Biotechnology Industry
Biotechnology Industry Environmental, Social and Governance Performance Analysis
Environmental Performance
Social Performance
Governance Performance
Consumer Perspective on ESG in Biotechnology
Case Study
Concluding Remarks from BCC Research

Chapter 12 Emerging Technologies and Developments

Drug Delivery to Lungs
Nanotechnology
Use of Artificial Intelligence and Machine Learning

Chapter 13 Clinical Trial and Patent Analysis

Clinical Trials Analysis
Patent Analysis

Chapter 14 Mergers and Acquisitions and Funding Outlook

Start-Up Funding in Nucleic Acid Delivery Technology

Chapter 15 Competitive Intelligence

Chapter 16 Company Profiles

ALNYLAM PHARMACEUTICALS INC.
ARCTURUS THERAPEUTICS INC.
ARBUTUS BIOPHARMA CORP.
ARROWHEAD PHARMACEUTICALS INC.
BENITEC BIOPHARMA
CELLECTA INC.
ELEVEN THERAPEUTICS
GENEVANT SCIENCES CORP.
IONIS PHARMACEUTICALS INC.
MIRIMUS, INC.
NOVO NORDISK
NANODE THERAPEUTICS INC.
OLIX PHARMACEUTICALS
PHIO PHARMACEUTICALS CORP.
SILENCE THERAPEUTICS PLC
SIRNAOMICS INC.
SOMAGENICS, INC.

簡介目錄圖表

List of Tables

Summary Table : Global Market for Nucleic Acid Drug Delivery, by Type, Through 2028
Table 1 : Challenges for the Delivery of Nucleic Acid Drugs
Table 2 : Differences Between Small Molecule Drugs and Biological Drugs
Table 3 : Nucleic Acid Drug Classification
Table 4 : Nucleic Acid Drug Types
Table 5 : siRNA Therapeutics for SARS-CoV-2, SARS-CoV-1 and MERS-CoV, 2021
Table 6 : Orphan Drug Incentives in Various Countries
Table 7 : Direct Methods of Insertion into the Cell
Table 8 : Advantages and Disadvantages of Various Kinds of Drug Delivery Systems
Table 9 : Advantages and Disadvantages of Viral Vectors
Table 10 : Global Market for Nucleic Acid Drug Delivery, by Encapsulation Material Type, Through 2028
Table 11 : Lipid Nanoparticles and Their Functions
Table 12 : Lipid Nanoparticle Types and Their Advantages and Disadvantages
Table 13 : Comparison of Polymeric Vectors and Lipid-Based Vectors
Table 14 : Polymer Types for Nucleic Acid Drug Delivery and Their Properties
Table 15 : Global Market for Nucleic Acid Drug Delivery, by Application, Through 2028
Table 16 : Approved Nucleic Acid Drugs, upto June 2023
Table 17 : Routes of Administration for Nucleic Acid Drugs
Table 18 : Global Market for Nucleic Acid Drug Delivery, by Route of Aministration, Through 2028
Table 19 : Characteristics of Different Molecule Types for Nucleic Acid Drug
Table 20 : Global Market for Nucleic Acid Drug Delivery, by Molecule Type, Through 2028
Table 21 : Comparison ASO Versus siRNA
Table 22 : Various mRNA Drugs Under Clinical Trials, June 2023
Table 23 : Comaprision of miRNA and siRNA
Table 24 : Global Market for Nucleic Acid Drug Delivery, by Therapeutic Area, Through 2028
Table 25 : Global Market for Nucleic Acid Drug Delivery, by Region, Through 2028
Table 26 : North American Market for Nucleic Acid Drug Delivery, by Type, Through 2028
Table 27 : North American Market for Non-Viral Vector Nucleic Acid Drug Delivery, by Type, Through 2028
Table 28 : U.S. Biotech Private Rounds for Nucleic Acid-Based, June 2022
Table 29 : European Market for Nucleic Acid Drug Delivery, by Type, Through 2028
Table 30 : European Market for Non-Viral Vector Nucleic Acid Drug Delivery, by Type, Through 2028
Table 31 : Asia-Pacific Market for Nucleic Acid Drug Delivery, by Type, Through 2028
Table 32 : Asia-Pacific Market for Non-Viral Vector Nucleic Acid Drug Delivery, by Type, Through 2028
Table 33 : Rest of the World Market for Nucleic Acid Drug Delivery, by Type, Through 2028
Table 34 : Rest of the World Market for Non-Viral Vector Nucleic Acid Drug Delivery, by Type, Through 2028
Table 35 : Alnylam ESG initiatives
Table 36 : Patents Issued on Nucleic Acid Drug Deivery, 2000-2020
Table 37 : Collaboration in Nucleic Acid Drug Delivery Market, 2021-2023
Table 38 : Start-Up Funding in the Nucleic Acid Drug Delivery Industry, January 2022 and March 2023
Table 39 : Collaborations in the Nucleic Acid Drug Delivery Market, 2021-2023
Table 40 : Clinical Trials and Approvals in the Nucliec Acid Drug Delivery Market, 2021-2023
Table 41 : Other Strategic Developments in Nucleic Acid Drug Delivery Market, 2021-2023
Table 42 : Alnylam Pharmaceuticals Inc.: Annual Revenue, 2022
Table 43 : Alnylam Pharmaceuticals: Pipeline Products
Table 44 : Alnylam Pharmaceuticals: Product Portfolio
Table 45 : Alnylam Pharmaceuticals: Recent Developments, 2021-2023
Table 46 : Arcturus Therapeutics Inc.: Annual Revenue, 2022
Table 47 : Arcturus Therapeutics: Pipeline Products
Table 48 : Arcturus Therapeutics: Recent Developments, 2021-2023
Table 49 : Arbutus Biopharma Corp.: Collaborations, 2021-2023
Table 50 : Arbutus Biopharma Corp.: Annual Revenue, 2022
Table 51 : Arbutus Biopharma Corp.: Recent Developments, 2021-2023
Table 52 : Pipeline of Arrowhead Pharmaceuticals
Table 53 : Benitec Biopharma: Annual Revenue, 2022
Table 54 : Eleven Therapeutics: Recent Developments, 2022
Table 55 : Genevant: Recent Developments, 2021 and 2022
Table 56 : Ionis Phamaceutical Inc.: Annual Revenue, 2022
Table 57 : Pipeline Products of Ionis Pharmaceuticals
Table 58 : Ionis Pharmaceuticals Inc.: Recent Developments, 2023
Table 59 : Mirimus Inc.: Recent Developments, 2021 and 2022
Table 60 : Novo Nordisk: Annual Revenue, 2022
Table 61 : Pipeline Products of Novo Nordisk
Table 62 : Pipeline Products of Nanode Therapeutics
Table 63 : Olix Pharmaceuticals: Recent Developments, 2021-2023
Table 64 : Slience Therapeutics: Annual Revenue, 2022
Table 65 : Pipeline of Silence Therapeutics
Table 66 : Silence Therapeutics: Recent Developments, 2023
Table 67 : Pipeline of Sirnaomics Inc.
Table 68 : Sirnaomics Inc.: Recent Developments, 2021-2023

List of Figures

Summary Figure : Global Market for Nucleic Acid Drug Delivery, by Type, 2020-2028
Figure 1 : Timeline of Nucleic Acid Therapeutics, Since 1950s
Figure 2 : Enzymes Needed for RNA-Based Drugs
Figure 3 : Basic Function of a Drug Delivery System
Figure 4 : Challenges Faced by RNA-Based Drug Delivery
Figure 5 : Nucleic Acid Drug Types
Figure 6 : Clinical Trial Flow
Figure 7 : Clinical Trial Specifications
Figure 8 : Share of Various Viruses Under Study for Vaccine Development
Figure 9 : Research on Virologoly During the COVID-19 Pandemic
Figure 10 : RNA-Based Drugs Under Development, 2017-2022
Figure 11 : Total RNA-Based Funding, by Venture Capitalists, 2017-2021
Figure 12 : Corporate-Backed RNA Financing, 2017-2021
Figure 13 : Financial Benefits for Orphan Drugs
Figure 14 : Nano-Delivery Types Used for Nucleic Acid Drug Delivery
Figure 15 : Global Market Shares of Nucleic Acid Drug Delivery Sytems, by Type, 2022
Figure 16 : Drug Delivery of Nucleic Acid Drugs, by Types
Figure 17 : Viral Vector Types
Figure 18 : Global Market for Conjugate Drug Delivery Systems of Nucleic Acids, 2020-2028
Figure 19 : Gene Therapy Types
Figure 20 : RNA-Based Drugs in Research and Development, 2022
Figure 21 : Initial Issues with RNA-Based Drugs
Figure 22 : RNA Drug Designing
Figure 23 : Market Breakdown by Route of Administration Types and Subtypes
Figure 24 : siRNA Delivery System
Figure 25 : Antisense Oligonucleotide Mechanism of Action
Figure 26 : Global Market Shares of Nulceic Acid Drug Delivery Systems, by Therapeutic Area, 2022
Figure 27 : Global Market for Nucleic Acid Drug Delivery, by Region, 2020-2028
Figure 28 : Share of Biotechnology Firms Reporting and Not Reporting ESG Data, 2022
Figure 29 : ESG Disclosure in Various Company Specific Documents in Biotechnology Industry, 2022
Figure 30 : Share of ESG Disclosure During the Forecasted Period in the Biotechnology Industry
Figure 31 : Share of ESG Significnace in the Biotechnology Industry
Figure 32 : Major Environmental Concerns in the Biotechnology Industry, 2023
Figure 33 : Major Social Concerns in the Biotechnology Industry
Figure 34 : Major Governance Concerns in the Biotechnology Industry
Figure 35 : Share of Clinical Trials of RNA Therapeutics, by Clinical Trial Phase, 2020-2022
Figure 36 : Share of Clinical Trials of RNA Therapeutics, by Age Group, 2022
Figure 37 : Share of Clinical Trials of RNA Therapeutics, by Gender, 2022
Figure 38 : Share of Clinical Trials of RNA Therapeutics, by Investors, 2022
Figure 39 : Share of Clinical Trials of RNA Therapeutics, by Recruitment Status, 2022
Figure 40 : Share of Clinical Trials of RNA Therapeutics Based on Study Results
Figure 41 : Start-Up Funding in the Nucleic Acid Drug Delivery Industry, by Various Rounds, 2022 and 2023
Figure 42 : Distribution Share of Start-Up Funding in the Nucleic Acid Drug Delivery Industry, by Various Rounds, 2022 and 2023
Figure 43 : Global Market Shares of Nucleic Acid Drug Deivery, by Various Growth Strategies, 2022
Figure 44 : Alnylam Pharmaceuticals: Annual Revenue, 2021 and 2022
Figure 45 : Alnylam Pharmaceuticals: Revenue Share, by Products, 2022
Figure 46 : Alnylam Pharmaceuticals: Revenue Share, by Region, 2022
Figure 47 : Arcturus Therapeutics: Annual Revenue, 2021 and 2022
Figure 48 : Arbutus Biopharma Corp.: Annual Revenue, 2021 and 2022
Figure 49 : Arbutus Biopharma Corp.: Revenue Share, by Type, 2022
Figure 50 : Benitec Biopharma: Annual Revenue, 2021 and 2022
Figure 51 : Ionis Phamaceutical: Annual Revenue, 2021 and 2022
Figure 52 : Novo Nordisk: Annual Revenue, 2021 and 2022
Figure 53 : Novo Nordisk: Revenue Share, by Segments, 2022
Figure 54 : Novo Nordisk: Revenue Share, by Region, 2022